Explore articles tagged with IndiaPharma
HRV Pharma Founder, MD & CEO Hari Kiran Chereddi shares insights in Express Pharma on India’s opportunity to become a strategic global CDMO partner through specialised capabilities, regulatory strength, scientific expertise and reliable execution.
The API industry is rethinking how manufacturing capacity and supply chains are structured, with manufacturing networks offering a more resilient approach through qualified partners, regulatory ownership and greater visibility.
HRV Pharma's RIKO is designed to bridge the gap between pharmaceutical manufacturers and customers. Drawing on millions of proprietary decisions across 55 countries, the AI-native platform supports faster partner qualification, transparent enquiry matching and early risk assessment across the pharmaceutical value chain.
In the pharmaceutical industry, identifying risks early can help prevent costly quality failures and recalls. PharmaClick explores how HRV Pharma's RIKO platform uses AI-driven pharmaceutical intelligence to assess chemistry risks, nitrosamine potential, supplier reliability and regulatory history before commitments are made.
Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.
HRV Pharma CEO Hari Kiran Chereddi explains why drug development success is now determined before manufacturing, driven by data, predictive analytics, and strategic decision-making.
HRV Pharma CEO Hari Kiran Chereddi shares insights on how platform-driven models are transforming pharma from factory-led systems to intelligent, network-based ecosystems.
HRV Pharma MD & CEO Hari Kiran Chereddi shares insights on how Indian CDMOs are transforming global pharmaceutical supply chains from risk-driven models to resilient, flexible, and strategic advantage.
HRV Pharma partners with Shodhana Laboratories to accelerate next-generation API development, combining AI-enabled virtual manufacturing with precision chemistry and global regulatory execution.
HRV Pharma (Group) has been recognised at the ET RE-Pharma Awards 2026 for Excellence in Pharma Global Business Support, highlighting its leadership in compliant, agile, and globally integrated pharmaceutical operations.
In BW Healthcare World, HRV Pharma MD & CEO Hari Kiran Chereddi outlines why API self-reliance has re-emerged as a strategic priority under Biopharma SHAKTI and what it means for India’s pharmaceutical future.
HRV Pharma CEO Hari Kiran Chereddi shares his insights on how Union Budget 2026–27’s focus on biopharma innovation, affordable cancer care, and healthcare infrastructure will shape India’s pharmaceutical future.
Virtual pharmaceutical manufacturing models are helping solve structural drug shortages by connecting global GMP capacity, improving supply flexibility, and strengthening regulatory execution.
HRV Pharma has entered a multi‑year strategic partnership with Haleos Labs to accelerate the development and manufacture of orphan and niche APIs, strengthening global access to complex therapies for rare diseases.
HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.
Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.
India's rise in biosimilars & biologics. Full clipping + insights included.